Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials.
Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. J Clin Oncol. 2008 Dec 10;26(35):5802-12. doi: 10.1200/JCO.2008.16.4368. Epub 2008 Nov 10. J Clin Oncol. 2008. PMID: 19001332 Free PMC article. Review.
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.
Vale CL, Burdett S, Rydzewska LHM, Albiges L, Clarke NW, Fisher D, Fizazi K, Gravis G, James ND, Mason MD, Parmar MKB, Sweeney CJ, Sydes MR, Tombal B, Tierney JF; STOpCaP Steering Group. Vale CL, et al. Lancet Oncol. 2016 Feb;17(2):243-256. doi: 10.1016/S1470-2045(15)00489-1. Epub 2015 Dec 21. Lancet Oncol. 2016. PMID: 26718929 Free PMC article. Review.
Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T, Mason MD, Miladinovic B, James ND, Parmar MKB, Spears MR, Sweeney CJ, Sydes MR, Tran N, Tierney JF; STOPCaP Abiraterone Collaborators. Rydzewska LHM, et al. Among authors: vale cl. Eur J Cancer. 2017 Oct;84:88-101. doi: 10.1016/j.ejca.2017.07.003. Epub 2017 Aug 8. Eur J Cancer. 2017. PMID: 28800492 Free PMC article. Review.
Re: Christopher J.D. Wallis, Zachary Klaassen, Bimal Bhindi, et al. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.10.002.
Vale C, Fisher D, Tierney J, White I, Sydes M, Carpenter J. Vale C, et al. Eur Urol. 2018 Mar;73(3):e49-e50. doi: 10.1016/j.eururo.2017.11.027. Epub 2017 Dec 9. Eur Urol. 2018. PMID: 29233663 No abstract available.
Response to letter commenting on published paper: Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
Rydzewska LHM, Burdett S, Vale CL, Parmar MKB, Tierney JF. Rydzewska LHM, et al. Among authors: vale cl. Eur J Cancer. 2018 May;94:218-219. doi: 10.1016/j.ejca.2018.02.002. Epub 2018 Mar 13. Eur J Cancer. 2018. PMID: 29548532 Free article. No abstract available.
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis.
Vale CL, Fisher DJ, White IR, Carpenter JR, Burdett S, Clarke NW, Fizazi K, Gravis G, James ND, Mason MD, Parmar MKB, Rydzewska LH, Sweeney CJ, Spears MR, Sydes MR, Tierney JF. Vale CL, et al. Ann Oncol. 2018 May 1;29(5):1249-1257. doi: 10.1093/annonc/mdy071. Ann Oncol. 2018. PMID: 29788164 Free PMC article.
67 results